leisure time -WSS

leisure time

author：focus 2025-08-05 20:18:27 - browse：6

Scientist pipetting in a biotech lab -- biotech coverage from STAT — A researcher working in the lab at Crinetics Pharmaceuticals in San Diego. Courtesy Crinetics

SAN DIEGO — Crinetics Pharmaceuticals announced on Sunday that its experimental drug for acromegaly, a rare and serious hormonal disorder, succeeded in a late-stage trial, bringing the San Diego biotech a step closer to applying for Food and Drug Administration approval — and entry into a crowded market with blockbuster therapies sold by pharma giants.

In the Phase 3 study, dubbed PATHFNDR-1, nearly 60 patients were randomly assigned to receive a placebo or a daily dose of paltusotine, an oral medicine designed to lower levels of growth hormone, which is produced in excess by people with acromegaly. After 36 weeks of treatment, 25 of the 30 patients given the drug had growth-factor levels that were within the normal range compared to just 1 of 28 participants who took the placebo, a difference that was statistically significant. Researchers also found that the treatment’s side effects were mild overall.

Crinetics plans to file for FDA approval if it gets positive results from a second, ongoing Phase 3 trial of the drug in acromegaly patients. The biotech expects results from that study, known as PATHFNDR-2, by the first quarter of next year.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Virginia high school admissions case could be legal follow
Next article： Device maker Teleflex to acquire urology company for $600M

WSS

Will the FTC rein in IQVIA's health data empire?

A new crop of companies is reshaping the health data economy

Dems pitch expanding Medicare power to negotiate drug prices

Bronny James, LeBron's son, suffers cardiac arrest during basketball practice at USC

What to watch for from Zogenix and Amicus clinical trials

STAT Summit: How a Chicago ER doctor tackles gun violence

knowledge

leisure time

focus

The high cost of giving birth even with insurance

The battle over 'scope creep' and who gets to be called 'doctor'

Virginia high school admissions case could be legal follow

Solve the antibiotic resistance crisis with preventive drugs

Apple is now the first public company to be valued at $3 trillion

UHS says company favors patients whose insurance pays more

Activists slam private health insurers over coverage restrictions

FDA gives detailed accounting of AI

Tori Bowie and the unacceptable rates of Black maternal death

First Opinion Podcast: Long Covid needs a new approach

entertainment

First Opinion Podcast: Long Covid needs a new approach

CDC Director Mandy Cohen on transparency, trust, and health

STAT Report: Patient voices and perspectives

Researchers explore possible ties between long Covid, menopause

Why health workers in Gaza are injured or die at high rates

Device maker Teleflex to acquire urology company for $600M

entertainment

hotspot

entertainment

hotspot